No Data
cabio biotech(wuhan) (688089.SH): has not yet involved in NMN related technology and research
On November 19th, Cabio Biotech (Wuhan) (688089.SH) stated on the interactive platform that the company uses synthetic biology as the underlying technology, cell factory as the preparation method, and sustainable biomanufacturing to provide high-quality nutrient products and innovative solutions for global nutrition and health customers. Currently, the main products include polyunsaturated fatty acids ARA, algae oil DHA, terpenes such as β-carotene, astaxanthin, carbohydrate substances SA and HMOs, widely used in the fields of infant formula milk powder, health food, animal nutrition, personal care and cosmetics, based on synthesis.
Cabio Biotech (Wuhan) (688089.SH): Currently equipped with small AIGC for fine-tuning training.
Gallop meeting on November 19th: Cabio Biotech(Wuhan) (688089.SH) stated on the interactive platform that, regarding the application of artificial intelligence in research and development, the company has explored the fields of synthetic biology and artificial intelligence. Currently, it has a small AIGC that can be fine-tuned through training. It can be specifically applied to organizing experimental reports, initial design of technical solutions, construction of literature knowledge graphs, and monitoring of product information markets. This helps improve the efficiency and quality of research and development, promotes the intelligence and automation of scientific research work, and provides strong intellectual support for R&D activities.
Cabio biotech(wuhan) (688089.SH): LNnT has completed the optimization of the small-scale fermentation process and has entered the pilot test stage.
GeLongHui November 19th | cabio biotech(wuhan) (688089.SH) stated on the interactive platform that the company has already developed a series of HMOs products including 2’-FL, 3-FL, 3’-SL, 6’-SL, LNnT, and has conducted related patent layout. According to the company's disclosed 2024 interim report, LNnT has completed the optimization of pilot-scale fermentation process and entered the pilot-scale testing phase. Other company-related patents are unrelated to our company.
Express News | More than 20 A-share listed companies disclosed the latest announcements on mergers and acquisitions this week. Xidiwei intends to purchase 100% of Chengxinwei's shares and will resume trading tomorrow.
Resumed trading with a one-character limit up, cabio biotech(wuhan) intends to acquire 65% equity of Eurobio symbol company with high debts.
1. Eurobio achieved a turnaround in profitability starting in 2023. From the first three quarters of 2022 to 2024, the target company achieved revenues of 0.265 billion yuan, 0.309 billion yuan, and 0.267 billion yuan respectively; 2. Xinda Securities stated that considering the closely related multiple group testing of the target company with cabio biotech(wuhan)'s existing synthetic biology research and development, it is expected that the two will form a strong synergistic effect.
Cabio Biotech(Wuhan) (688089.SH): intends to acquire 65.00% equity of EU Bio from November 12 and will resume trading.
On November 11th, Cabio Biotech (wuhan) (688089.SH) announced that the company plans to purchase 65.00% equity of Ouyi Biotech from 14 trading partners including Wang Shuwei, Dong Dong, Xiao Yunping, Wang Xiuping, Jin Chao, Shi Xianjun, Shanghai Fanyi, Ningbo Ruio, Ningbo Ouren, National Pharmaceutical Phase II, Nantong Dongzheng, Suzhou Dingshi, Shanghai Biology, Shanghai Shengqi, through the issuance of shares and cash payment, and raise supporting funds. The final transaction price of the target assets will be based on the evaluation results of the evaluation report issued by the asset evaluation institution in accordance with the Securities Law, and will be determined through full negotiation between the two parties. The target company consists of multiple
No Data
No Data